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A crucial early event by which cancer cells switch from localised to invasive phenotype is initiated by the acquisition of autonomous
motile properties; a process driven by dynamic assembly and disassembly of multiple focal adhesion (FA) proteins, which mediate
cell–matrix attachments, extracellular matrix degradation, and serve as traction sites for cell motility. We have reported previously
that cancer cell invasion induced by overexpression of members of the ErbB tyrosine kinase receptors, including ErbB2, is dependent
on FA signalling through FA kinase (FAK). Here, we show that ErbB2 receptor signalling regulates FA turnover, and cell migration and
invasion through the Src–FAK pathway. Inhibition of the Src–FAK signalling in ErbB2-positive cells by Herceptin or RNA interference
selectively regulates FA turnover, leading to enhanced number and size of peripherally localised adhesions and inhibition of cell
invasion. Inhibition of ErbB2 signalling failed to regulate FA and cell migration and invasion in cells lacking FAK or Src but gains this
activity after restoration of these proteins. Taken together, our results show a regulation of FA turnover by ErbB2 signalling.
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The ability of invasive tumour cells to invade surrounding tissue
structures at primary sites requires tumour cell capacity to become
motile and invasive. This process involves a series of cellular
events, which includes formation and extension of protrusions in
response to chemotactic signals, formation of stable cell focal
adhesion (FA)–matrix attachment near the leading edge of the
protrusions, and movement of the cell body forward aided by the
release and retraction of the FAs at the trailing edge of the cell.
Therefore, FAs are established as key regulators of cell motility and
cell invasion since they can act as signalling centres and provide
robust anchors to the extracellular matrix (ECM), which represent
traction points for the generation of cell tension and motility.
Several protein kinases and phosphatases appear to be central to
the regulation of adhesion turnover and stability, including the FA
kinase (FAK). We have reported that ErbB2-induced cell invasion
is dependent on FAK signalling (Benlimame et al, 2005). Focal
adhesion kinase is a key multifunctional adaptor and signalling
molecule that has been shown to play a role in FA formation and
turnover and is required for cell motility and cell invasion
(Ilic et al, 1995; Sieg et al, 2000). In motile cells, FAK along with
other partners of the FA network is recruited to membrane cell
protrusion following integrin engagement and/or receptor activa-
tion, where it becomes autophosphorylated at tyrosine Y397. Src is
then recruited through its SH2 domain to the phosphorylated FAK,
and both enzymes subsequently phosphorylate additional FAK
tyrosine residues in the catalytic and C-terminal domains creating
additional docking sites for SH2-containing proteins (Schaller
et al, 1994; Calalb et al, 1995; Parsons et al, 2000). Similar to FAK,
Src also regulates FA dynamics and both FAK- and Src-deficient
fibroblasts have motility defects and stable FAs attributed to
defective FA turnover required for cell locomotion.
In this study, we established a functional role for ErbB signalling
in the regulation of FA turnover in invasive cells through the Src–
FAK pathway, and provided a novel mechanism for the anti-ErB2
antibody Herceptin in inhibiting FA turnover and preventing the
early stage cancer invasion.
MATERIALS AND METHODS
Antibodies and reagents
Antibodies for ErbB2 and Src were from Oncogene (Boston, MA,
USA). Antibodies to Akt1, phospho-Akt (Ser473), ERK1/2, and
phospho-ERK (Tyr202/Tyr204) were from Cell Signaling Technology
(Beverly, MA, USA). Antibodies to phosphotyrosine and ERK2 were
from Upstate Biotechnology (Waltham, MA, USA). Antibodies to
RhoA and phospho-FAK-Y925 were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies to FAK, phospho-FAK-Y397,
and phospho-FAK-Y861 were from Biosource International
(Camarillo, CA, USA). Antibody to vinculin was from Sigma-Aldrich
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s(St Louis, MO, USA). Antibody to GAPDH was from Cedarlane
(Burlington, Ontario, Canada), and antibody to a-tubulin was from
Abcam (Cambridge, MA, USA). Heregulin b-1 (HRG b1) was from
Neomarkers (Fremont, CA, USA). Fibronectin and nocodazole were
from Sigma-Aldrich. Taxol and Herceptin were from the Oncology
pharmacy of the Jewish General Hospital.
Cell culture
Cells MCF-7, MDA-231, T47D, and BT20 were obtained from
ATCC and maintained in RPMI 1640 (Mediatech, Washington, DC,
USA). SKBR3 cells were maintained in McCOY’s medium (Wisent
Inc. St-Bruno, Quebec, Canada). Mouse embryonic fibroblasts FAK
proficient (FAK
þ/þ) and FAK deficient (FAK
 / ) were provided
by Dr Dusko Ilic (University of California, San Francisco, CA,
USA) and maintained as described by Ilic et al (1995). SYF cells
(Src, Yes, and Fyn triple knockout) and Src reconstituted SYF cells
were from the ATCC, and were maintained in DMEM. All the
media were supplemented with 10% FBS and penicillin and
streptomycin antibiotics.
ErbB2 receptor was overexpressed using a bicistronic retro-
vector that coexpresses ErbB2 receptor with the enhanced green
fluorescent protein (EGFP) as described earlier (Yen et al, 2002).
Focal adhesion kinase reconstitution in FAK-deficient cells was
achieved by the expression of pBabe-GFP-mFAK-puro retroviral
particles (kindly provided by Dr D Schlaepfer, the Scripps
Institute) as described earlier (Bergeron et al, 2000).
Generation of cells expressing siRNA FAK and siRNA Akt-1
Stable FAK and Akt1 knockdown cells were generated in a
polyclonal population as described by Benlimame et al (2005).
Focal adhesion kinase-1: gcatgtggcctgctatgga; FAK-2: gccttaa
caatgcgtcagt; Akt1-1: ggagatcatgcagcatcgc; Akt1-2: acgaggggagtac
atcaagtc are the target sequences used for stable knockdown of
FAK and Akt1.
Cell proliferation assay
Cells (1 10
3) were seeded in 96-well plates and incubated for 16h.
In the presence of mouse IgG1 as control or 5mgml
 1 Herceptin,
cells were then treated with 10ngml
 1 heregulin. Cell survival was
evaluated 96h later using the 3-(4,5-dimethylthiazo-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) metabolic assay as de-
scribed earlier (Yen et al, 2002).
Immunoprecipitations and western blot analysis
Immunoprecipitation and western blot were carried out as we
described earlier (Benlimame et al, 2005). Blots were detected
using appropriate antibodies and visualised by enhanced
chemiluminescence detection.
RhoA GTPase activation assay
Cell extracts were collected from nocodazole-treated MDA231-
ErbB2 cells immediately after 4h nocodazole treatment (0min)
and 60min after growth in nocodazole-free medium, in the
presence of mouse IgG1 as control or 5mgml
 1 Herceptin.
Activated RhoA-GTPase level was determined by immunoprecipi-
tation using the rhotekin-binding domain (Ren et al, 2000)
coupled to western blot analysis using anti-RhoA. Whole cell
lysates were reprobed for total RhoA.
FAK and Src kinase assays
Cells at 80% confluence were serum-starved for 24h, pretreated
with either 5mgml
 1 Herceptin or IgG1 in serum-free medium and
then stimulated with 10ngml
 1 heregulin for the indicated time.
Cells were washed with cold PBS, and 500mg of total cell lysate
were used for immunoprecipitation with FAK antibody. Focal
adhesion kinase assay was performed as described by Sieg et al
(2000). Src kinase assay was performed based on a protocol
described by Nagata et al (2004).
Focal adhesion disassembly assay
Assay for FA disassembly and reformation after nocodazole
treatment has been described earlier (Ezratty et al, 2005). Serum-
starved cells were grown on glass coverslips and incubated with
Herceptin (5mgml
 1) or mouse IgG1 for 1h followed by 10mM
nocodazole treatment for 4h. Nocodazole was washed out with
serum-free medium, cells were fixed and stained with vinculin,
phospho-FAK-Y397, and/or a-tubulin.
Indirect immunofluorescence analysis
Cells were seeded on fibronectin-coated coverslips for 2 days at a
density of 20000–50000 cells per 35mm dish, incubated for 24h
in serum-free medium and then pretreated with 5mgml
 1
Herceptin or mouse IgG1 before adding 10ngml
 1 HRG b1. The
cells were fixed, permeabilised, labelled for immunofluorescence
and analysed using florescence microscopy as we described earlier
(Yen et al, 2002; Benlimame et al, 2005).
Invasion and cell migration assay
Cell invasion experiments were performed with 8-mm porous
chambers coated with Matrigel (Becton Dickinson, Franklin Lakes,
NJ, USA) according to the manufacturer’s recommendations. Cell
migration was assayed using the qualitative wound-healing assay
as described earlier (Benlimame et al, 2005).
Time-lapse video microscopy
For live fluorescent imaging, the BT20 cells were stably transfected
with EYFP-paxillin and plated in RPMI-1640 on a multi-well
Chambered coverglass (Lab Tek, nunct, Rochester, NY, USA)
coated with 10mgml
 1 fibronectin for 1h. Before filming, media
was replaced with complete RPMI-1640 media supplemented with
either IgG1 control or 5mgml
 1 Herceptin in different wells. Cells
were placed directly on a heated stage and supplemented with 5%
CO2. Fluorescent images were captured every 1min for 2h using a
heated  100/1.40NA objective at the optimised Nipkow Spinning
Disk confocal microscope (Quorum Technologies Inc., Guelph,
Ontaria, Canada). Cooled CCD camera control and image
acquisition was done using Volocity imaging software (Improvision,
Waltham, MA, USA). At the extremely high speed, we investigated
different cells in less than 10s interval. The experimental results
show representative cells from a minimum of five different
experiments. Fluorescence intensities of individual adhesions from
background-subtracted images were measured over time using
volocity imaging software. Measurements were made on at least 25
individual adhesions in five separate cells for both control IgG1- and
Herceptin-treated cells. Data are presented as mean±s.d. Statistical
significance was analysed using Student’s t-test.
RESULTS
ErbB signalling modulates cell invasion in an
FAK-dependent manner
To address the impact of ErbB signalling on cell invasion, we used
a panel of human breast cancer cell models overexpressing
exogenous ErbB2 (MCF7 and MDA231), endogenous ErbB2
(SKBR3 and T47D), or MDA231 cell variant (MDA231-M) selected
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sin vivo from a metastatic lung nodule induced by MDA231-ErbB2
cells after implantation into the mammary fat pad. In addition,
mouse embryonic fibroblasts proficient (FAK
þ/þ) or deficient
(FAK
 / ) in FAK and overexpressing ErbB2 were used. ErbB2 was
overexpressed using a retroviral system that expresses both the
EGFP and the receptor (Benlimame et al, 2005). Figure 1
summarises the expression status of ErbB2 in these cells
(Figure 1A) and following receptor activation with 10ngml
 1
HRG b1. Heregulin b1 is the ligand for ErbB-3 and ErbB-4, which
activates ErbB2 by inducing receptor heterodimerisation and
transphosphorylation. As noted, the basal phosphorylation level of
ErbB2 is increased even in the absence of ligand stimulation
(Yarden and Sliwkowski, 2001). As shown in Figure 1B, in all cell
lines tested, ErbB2 is autophosphorylated in cells overexpressing
the receptor, and exposure to HRG b1 further enhances receptor
phosphorylation. In the parental cells used to overexpress ErbB2,
the levels of ErbB2 protein and receptor phosphorylation ranged
from being very weak to undetectable (Yen et al, 2002; Benlimame
et al, 2005).
To address the impact of ErbB2 signalling on FAs, cell invasion,
and cell proliferation, we examined the impact of ErbB2 signalling
modulation by Herceptin. We initially confirmed the responsive-
ness of ErbB2-positive cells to Herceptin focusing on the MDA231-
ErbB2 and SKBR3 cell lines. In this case, cells were exposed to
5mgml
 1 Herceptin and monitored for the activation of Akt1 and
mitogen-activated protein kinase (MAPK), Rapid Akt1 and MAPK
dephosphorylation following Herceptin treatment as reported
earlier (Ignatoski et al, 2000; Yakes et al, 2002; Nagata et al,
2004). As shown in Figure 2A, Herceptin inhibited active MAPK
and active Akt1 as measured by antibodies specific to phospho-
MAPK and phospho-Ser473 Akt1, respectively.
Cells were then serum-starved and stimulated with HRG b1, in
the presence of mouse IgG1 or 5mgml
 1 Herceptin. Cell
proliferation was determined by the MTT assay. Cell invasion
experiments were performed using the Matrigel Boyden chamber
assay. HRG b1 was added into the lower compartment of the
chamber as a chemotactic reagent. As shown in Figure 2B, ErbB2
modulation by Herceptin had a modest inhibitory effect on the
proliferation of ErbB2-positive cell lines, and no significant cell
death was observed after 72–96h cell exposure to Herceptin (not
shown). In contrast, Herceptin treatment induced a potent
reduction in the invasion of ErbB2þ cells (Po0.005, compared
with control cells).
To address the importance of FAK on cell invasion following
ErbB2 modulation, we compared Herceptin activity in FAK-
proficient and FAK-deficient mouse embryonic fibroblast cells
overexpressing ErbB2 (FAK
þ/þ-ErbB2 and FAK
 / -ErbB2,
respectively) (Figure 1A). Herceptin can target human ErbB2
overexpressed in mouse fibroblasts in human cells (Mandler et al,
2004, and unpublished data). The invasive capacity of FAK
 / -
ErbB2 cells was slightly increased compared with FAK-deficient
cells, but remained significantly lower than FAK
þ/þ-ErbB2 cells
(Po0.01) (Figure 2C). Herceptin was less effective in FAK
 / -
ErbB2 cells as compared with FAK
þ/þ-ErbB2 cells. Interestingly,
re-expression of wild-type FAK restored the inhibitory activity
of Herceptin in FAK
 / -ErbB2 cells to a level that approached
MDA231
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– + – + – + – +
MCF7-ErbB2 SKBR3
IP:ErbB2
IP:ErbB2 HRG
pTyr
T47D
C
M
ErbB2
ErbB2
GAPDH
ErbB2
GAPDH
FAK
–/–
FAK
–/–  -ERbB2
FAK
+/+  -ERbB2
FAK
+/+
CM ErbB2
MC F7
T47D
SKBR3 A
B
Figure 1 Overexpressed ErbB2 receptor is activated by heregulin b1 in the cancer cell models used. (A) Total cell lysates were isolated from parental
cells (C), ErbB2 overexpressing cells (ErbB-2), and a metastatic cell variant selected in vivo from a lung metastatic nodule induced by MDA231-ErbB2 cells
implanted into the mammary fat pad (MDA231-M). Proteins were resolved by SDS–PAGE and immunoblotted with anti-ErbB2 antibody. As an internal
control GAPDH was used. (B) Cells were serum-starved for 24h and then stimulated with 10ngml
 1 HRG b1 for 10min. ErbB2 was immunoprecipitated
from total cell lysates, resolved by SDS–PAGE, and blots were probed using a phosphotyrosine antibody and reprobed with antibody against ErbB2, as
described in Materials and Methods.
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sFAK
þ/þ-ErbB2 cells (Figure 2C). In a similar manner as the cell
invasion assay, the requirement of FAK was also observed for
Herceptin-induced inhibition of cell migration on the wound-
healing assay (Figure 2C).
To reinforce the connection between FAK and ErbB2 signalling
in relation to cell invasion, we showed that the anti-invasive
activity following modulation of ErbB2 signalling by Herceptin is
similar to the inhibitory effect obtained when FAK expression was
Hcp
C
e
l
l
 
p
r
o
l
i
f
e
r
a
t
i
o
n
(
%
 
c
o
n
t
r
o
l
±
s
.
d
.
)
C
e
l
l
 
p
r
o
l
i
f
e
r
a
t
i
o
n
(
%
 
c
o
n
t
r
o
l
±
s
.
d
.
)
N
o
.
 
o
f
 
i
n
v
a
s
i
v
e
 
c
e
l
l
s
(
m
e
a
n
±
s
.
d
.
)
N
o
.
 
o
f
 
i
n
v
a
s
i
v
e
 
c
e
l
l
s
(
m
e
a
n
±
s
.
d
.
)
N
o
.
 
o
f
 
i
n
v
a
s
i
v
e
 
c
e
l
l
s
(
m
e
a
n
±
s
.
d
.
)
AKT1
pERK
ERK1/2
pAKT1-s473
– + – + 100
140
180
400
IgG
0 h 18 h
Hcp
FAK
GAPDH
AKT
GAPDH
300
200
100
0
150
120
90
60
30
0
120
100
80
60
40
20
0
500
IgG
HCP
400
300
200
100
80
60
40
20
0 0
SKBR3
Control
siFAK
siAKT
Hcp
FAK
–/–
FAK
–/–
FAK
+/+
FAK
+/+
FAK
+/+ -ErbB2
FAK
+/+ -ErbB2
FAK
–/– -ErbB2
FAK
–/– -ErbB2
FAK
–/– -ErbB2-FAK
FAK
–/– -ErbB2
IgH1
FAK
–/– -ErbB2
Hcp
FAK –/– -ErbB2
+ FAK
IgG1
FAK –/– -ErbB2
+ FAK
Hcp
FAK
–/– -ErbB2-FAK
SKBR3
MD A231-ErbB2
MDA231-ErbB2
MD A231-M
PSR-FAK-1
PSR-FAK-2
PSR
PSR-FAK-1
PSR-FAK-2
PSR
MDA231-M
MCF7-ErbB2
MCF7-ErbB2
SKBR3 MDA231-ErbB2
Figure 2 Herceptin induces downregulation of Akt and ERK signalling in ErbB2-positive cells, and inhibits cell invasion in a FAK-dependent manner.
(A) Impact of Herceptin (Hcp) (þ,5mgml, 48h) or control IgG1 ( ,5mgml
 1, 48h) on the expression and phosphorylation levels of Akt1 and MAPK-ERK
in MDA231-ErbB2 and SKBR3 cells using western blot on total cell extracts. (B) Left panel: the rate of cell proliferation was similar between Herceptin-
treated and control IgG1-treated cells using the MTT assay. Cell proliferation (expressed as % of control cells) was monitored by the MTT assay. Results are
expressed as the average of four independent experiments±s.d. Right panel: herceptin inhibits cell invasion on the Boyden chamber invasion assay. Results
are expressed as the mean of at least three experiments and three fields per condition±s.d. (C) FAK-deficient (FAK
 / -ErbB2) and FAK-proficient
(FAK
þ/þ-ErbB2) cells were used to show the essential role of FAK in Herceptin-induced inhibition of cell proliferation and cell invasion using similar
conditions described in (B). Results are expressed as mean±s.d. Figure on the right is a representative wound-healing experiment on ErbB2-FAK-proficient,
ErbB2-FAK-deficient, and ErbB2-FAK-reconstituted cells treated with IgG1 or 5mgml
 1 Herceptin. Note the requirement of FAK for Herceptin-induced
inhibition of cell migration. (D) Left panel: representative western blots showing FAK and Akt1 expression in MDA231-ErbB2 cells stably engineered to
express FAK siRNA or Akt1 siRNA using pSuper-retro puro vector. Control cells expressed retroviral vector pSuper-retro-puro alone (PSR). As an internal
control GAPDH was used. Right panel: cell invasion was examined on MDA231-ErbB2 cells expressing PSR (control), FAK siRNA, Akt siRNA, or treated
with 5mgml
 1 Herceptin as described in (B) (legend for the right panel). For each condition, the experiments was performed three times and the results are
expressed as mean±s.d.
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sdownregulated by siRNA in MDA231-ErbB2 cells (Figure 2D). In
contrast, inhibition of Akt1 by siRNA to a level that is equal or
greater following Herceptin treatment had only a modest but not
statistically significant inhibitory effect on cell invasion
(Figure 2D). These data support the requirement of FAK for
Herceptin-induced anti-invasive activity in ErbB2-positive cells.
ErbB signalling regulates focal adhesion turnover in an
FAK- and Src-dependent manner
Focal adhesion kinase is an adaptor protein that undergoes
multiple phosphorylations and protein–protein interactions. As
shown in Figure 3A, exposure of serum-starved MDA231-ErbB2
and SKBR3 cells to 5mgml
 1 Herceptin for 1h followed by 15min
stimulation with HRG b1 had no clear effect on FAK phosphoryla-
tion at tyrosine 397; however, reduced phosphorylation was
observed at tyrosines 861 and 925.
However, immunofluorescence microscopy showed significant
differences in the appearance and distribution of FAs in ErbB2
overexpressing cells, as compared with parental cells. As shown in
Figure 3B, control cells formed large and elongated FAs (shown by
phospho-FAK Y397, an activation site of FAK that becomes
phosphorylated upon FA assembly) that were most prominent at
the cell periphery. In contrast, cells that overexpressed ErbB2
formed small and short punctuate phospho-FAK Y397 containing
adhesions. These finding suggest that ErbB2 signalling plays a role
in the regulation of FA dynamics.
To determine whether ErbB2 signalling is important for FA
disassembly, we examined the localisation and appearance of FAs
following ErbB2 modulation by Herceptin. As shown in Figure 3C,
compared with ErbB2-positive cells treated with IgG1, exposure to
5mgml
 1 Herceptin for 1h clearly induced changes in the
appearance of peripherally localised FAs, such as phospho-FAK
Y397, paxillin, and vinculin (data not shown), which increased in
number and size and became homogeneously distributed along the
plasma membrane. As noted for cell invasion, Herceptin did not
affect FAs in cells lacking FAK (Figure 3D), but restoration of FAK
in these cells rescued Herceptin activity on FAs resulting in a
similar appearance as in FAK
þ/þ-ErbB2 cells.
The reorganisation and increased density and size of FAs seen at
the cell membrane following inhibition of ErbB2 signalling by
Herceptin suggests a change in FA turnover. To address this
hypothesis, we used the the nocodazole-based assay (Ezratty et al,
2005). Treatment of cells with the microtubule-disrupting agent
nocodazole inhibits microtubule targeting and focal complex
disassembly. After nocodazole washout, microtubule targeting of
focal complexes occurs and promotes focal complex turnover and
cell spreading. As shown in Figure 4A, exposure of serum-starved
MCF7 cells to nocodazole induced strong FA formation followed
by disassembly and then reassembly after nocodazole washout.
Interestingly, MCF7-ErbB2 cells showed more rapid loss of
phospho-FAK Y397 compared with MCF7 control cells, which
had more prominent and stable FAs (30 and 60min after
nocodazole washout). We then examined how ErbB2 modulates
the organisation and disassembly of FAs after Herceptin stimula-
tion. We observed that exposure of MCF7-ErbB2 cells to 5mgml
 1
Herceptin induced more stable (30 and 60min after nocodazole
washout) FAs, as compared with IgG1-treated control cells. In
contrast, there was no significant change in FAs disassembly
following Herceptin treatment in the parental MCF7 ErbB2-
negative cells (data not shown).
Under similar conditions, serum-starved MDA231-ErbB2 cells
have reduced FAs as shown by phospho-FAK 397 staining
(Figure 4B). Exposure of these cells to nocodazole increased FA
formation followed by a rapid disassembly (30min), following
nocodazole washout as seen in the control. Focal adhesion reform
and appear larger and prominent. Exposure of these cells to
5mgml
 1 Herceptin induced a more stable and rapid recovery
(60min) of FAs, as compared with IgG1-treated control cells
(Figure 4B). The number and size of FAs formed under each
condition was quantified using Volocity software. Quantified data
were obtained from an average of 20 cells of each condition from
three independent experiments. Herceptin treatment increased the
number of FA by approximately 60% (Po0.05) at the control basal
level and 120min after nocodazole washout, and became
approximately three-fold at 60min after nocodazole washout
(Po0.001). At the same time, Herceptin treatment also slightly
increased the size of FAs.
To check biochemically for FA disassembly, we monitored levels
of FAK-pY397 by western blot (Figure 4C). The levels of FAK-
pY397 decreased after nocodazole washout and were roughly
correlated with the loss of FAs detected by immunofluorescence
(Figure 4B). The more rapid recovery of FAK-pY397 in the
Herceptin-treated MDA231 ErbB2 cells were also observed in the
biochemistry (plastic) substrate.
The difference in the kinetics of FA turnover between MCF7-
ErbB2 and MDA231-ErbB2 is likely due to the genetic background
of these cells. As reported in the Supplementary data Figure 1A,
ErbB2 signalling does not affect microtubule organisation. In
addition, the differential effect of Herceptin on FA turnover is not
due to a possible differential regulation of RhoA, as the expression
level of activated RhoA-GTPase in MDA231-ErbB2 was not affected
by Herceptin treatment (Supplementary data, Figure 1B; the
average densitometry ratios of active RhoA/RhoA were: 1.37±0.21
and 1.43±0.19 for cells collected immediately after nocodazole
treatment (0min) in the absence and presence of Herceptin, and
1.51±0.22 and 1.27±0.19 for cells collected 60min after
nocodazole washout in the absence and presence of Herceptin,
respectively). Moreover, similar data on Herceptin-mediated
regulation of FA turnover was observed in T47D cells, a breast
cancer cell line that express intermediate endogenous ErbB2
(Supplementary data Figure 1C).
The above results on the regulation of FA turnover by ErbB2
signalling were also confirmed using time-lapse video microscopy
on BT20 breast cancer cells (these cells express high level of
endogenous ErbB2 and are responsive to Herceptin, Yakes et al,
2002; Nagata et al, 2004) transfected with EYFP-paxillin. As shown
in Figure 4D, FAs containing EYFP-paxillin became larger, more
peripheral and stable in cells treated with Herceptin compared
with control cells treated with IgG1 (a related video is included in
Supplementary data). We measured the duration of EYFP-paxillin
intensity in forming or disassembling FAs of control and
Herceptin-treated cells (Figure 4D right panel) as performed by
Franco et al (2004). EYFP-paxillin in these cells showed the
persistence of paxillin in adhesion complex for extended durations
in the treatment of Herceptin. This further established a regulation
of FA turnover following modulation of ErbB2 signalling by
Herceptin in alternative ErbB2-positive cancer cells.
Focal adhesion turnover is regulated through an assembly and
disassembly process, where the Src–FAK complex plays an
essential role (Webb et al, 2004; Yeo et al, 2006). ErbB2 interacts
with cytoplasmic c-Src (Belsches-Jablonski et al, 2001). It is the
dual FAK–Src complex that regulates subcellular localisation of
FA proteins at cell protrusions (Richardson et al, 1997; Schaller
et al, 1999). On the basis of these observations, we sought to
examine if Src plays a role in Herceptin-induced regulation of FAs
in ErbB2-positive breast cancer cells. It has been reported that
Herceptin treatment induced a rapid dissociation of Src from
ErbB2, leading to inhibition of Src kinase activity (Nagata et al,
2004). Focusing on MDA231-ErbB2 cells, we observed that
treatment with 5mgml
 1 Herceptin reduced ErbB2/Src interaction
(Figure 5A) and Src kinase activity (Figure 5B). Interestingly,
Herceptin also reduced FAK activity in a time-dependent manner
(Figure 5C).
To confirm that the regulation of FA turnover by ErbB2 and
Herceptin is dependent upon FAK and Src, we examined FA
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Figure 3 Herceptin induces downregulation of FAK phosphorylation at Y861 and Y925, and reorganisation of focal adhesions at cell membrane. (A) SKBR3 and
MDA231-ErbB2 cells at 70% confluence were serum-starved for 24h, treated with IgG1 ( )o r5mgml
 1 Herceptin (Hcp) (þ) for 1h and then stimulated with
10ngml
 1 HRG b1 for 10min. Equal amounts of proteins were immunoprecipitated with anti-FAK. Blots were probed with antibodies against phosphotyrosine,
phospho-FAK-Y397, phospho-FAK-Y861, phospho-FAK-Y925, and FAK. (B) Cells were fixed and immunostained with phospho-FAK-397, a marker of FAs. Control
cells showed larger, elongated FAs at the cells periphery. In contrast, ErbB2 overexpressing cells showed punctuate phospho-FAK397-containing adhesions. White
arrows show the position of adhesive contact sites. Scale bar, 30mm. (C) Cells were treated as described in (A) and then fixed and immunostained with phospho-FAK-
397. Note that control cells exhibit a homogenous subcellular localisation of FAs, whereas in cells treated with Herceptin, FAs are prominently localised at the periphery
of cell protrusions (ring-like shape) as shown in the enlargements of the boxed regions. Scale bar, 30mm. (D) FAK
þ/þ-ErbB2 and FAK
 / -ErbB2 cells were treated
under similar conditions as in (A). Immunofluorescence labelling of phospho-FAK-Y397 or vinculin showed that under Herceptin treatment, FAK
þ/þ-ErbB2 cells
exhibited larger FAs within the cell protrusions, whereas the FAK
 / -ErbB2 cells remained unchanged with large vinculin-containing adhesions. In contrast, the
restoration of wild-type FAK in FAK
 / -ErbB2 cells exhibited a robust staining of phospho-FAK-Y397 at the cell protrusions under Herceptin treatment compared with
the control, where the phospho-FAK-Y397 is localised at small and numerous focal contacts. Scale bar, 30mm.
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sturnover in matched ErbB2-FAK-deficient and ErbB2-Src-deficient
cells and their respective reconstituted cells (Figure 6A). Micro-
tubule regrowth failed to induce FA disassembly in FAK
 /  cells,
and Herceptin failed to regulate FA turnover as shown with
vinculin staining. However, microtubule regrowth did induce FA
disassembly in FAK
 /  cells where FAK is re-expressed. Also
Herceptin regained its effect on FA turnover with rapid recovery of
FAs compared with control IgG1-treated cells (Figure 6B). There-
fore, these results indicate that FAK is required for both
microtubule-induced FA disassembly and Herceptin-mediated FA
regulation.
In a similar manner, we examined the impact of Src on
Herceptin-induced regulation of FA turnover using the SYF cells
(triple knockout for Src, Yes, and Fyn) and Src-reconstituted SYF
cells engineered to overexpress ErbB2 (Figure 6A). In SYF cells,
although FA disassembly occurred normally (Ezratty et al, 2005),
FA regeneration was defective (Yeo et al, 2006). This defect in FA
reassembly is consistent with Src being essential to the activation
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Figure 4 Herceptin regulates the turnover of focal adhesions. (A) Serum-starved control MCF7 and ErbB2 cells were incubated with mouse IgG1 ( )o r
5mgml
 1 Herceptin (þ) for 1h followed by 10mM nocodazole (NZ) treatment for 4h. At the indicated time after nocodazole washout, cells were stained
with anti-phospho-FAK-Y397 antibody. Control serum-starved cells exhibit few punctuate FAs, which localise around the cell periphery in the presence of
Herceptin. Exposure to nocodazole increased the number of FAs (0min) followed by a rapid disassembly and then reassembly after nocodazole washout
(30 and 60min). Note that MCF7-ErbB2 cells showed more rapid loss of p-FAK397, as compared with MCF7 control cells, which showed prominent and
stable focal adhesions (30 and 60min). Notably, exposure of MCF7-ErbB2 cells to 5mgml
 1 Herceptin further induced stable FAs (30 and 60min after
nocodazole washout), as compared with IgG1-treated control cells. Scale bar, 30mm. (B) Top panel: serum-starved MDA231-ErbB2 cells taken from
duplicate conditions described in (A) were immunolabeled with anti-phospho-FAK-Y397 and anti-vinculin antibodies simultaneously. Note that Herceptin
induced a more rapid recovery of FAs compared with control cells (60min). Scale bar, 30mm. Lower panel: quantification of number and size of focal
adhesion by Volocity imaging software. Quantified data were obtained from an average of 20 cells of each condition from three independent experiments.
Treatment of Herceptin increased both the number and size of focal adhesions when compared with control cells (*Po0.05; **Po0.001).
(C) Representative western blot of focal adhesion disassembly assay. Serum-starved MDA 231 ErbB2 cells were incubated for 4h with 10mM nocodazole
(NZ) treatment, and the drug was then washed out and microtubules were allowed to regrowth. Cell lysates were prepared at the indicated times as in (B)
and separated by SDS–PAGE and western blot was performed. Immunoblotting with the corresponding antibodies showed that the levels of p-FAK-Y397
decreased after nocodazole washout and were roughly correlated with the loss of focal adhesions detected by immunofluorescence. Herceptin-treated
MDA231 ErbB2 cells showed more rapid recovery of p-FAK-Y397 compared with control cells. (D) Left panel: Herceptin-A induced stabilisation of focal
adhesions in real time live cells. BT20 cells stably expressing EYFP-paxillin were plated on fibronectin-coated multi-well chamber coverslides. Video
sequences of magnified regions of cells treated with either IgG1 (control) or 5mgml
 1 Herceptin (Hcp) were monitored at 5min intervals (t¼0, 5, 10, 15,
20min). Focal adhesions containing EYFP-paxillin were larger, and more peripheral and stable in cells treated with Herceptin compared with IgG-treated
control cells, which have smaller and more dynamic EYFP-paxillin containing adhesions. White arrows show the position of stabilised focal adhesion sites.
Scale bar, 10mm. (see Supplementary data for the related real-time movie). Right panel: quantification of the persistence of EYFP-paxillin in adhesion
complexes shows that paxillin persists for longer durations upon incubation of Herceptin. Duration of measurements were made by counting the amount of
time lapsed between the first and last frames in which an individual adhesion was observed. Quantifications show the mean±s.d. (*Po0.001).
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sof FAK, which is essential for FA regulation. As shown in
Figure 6C, although FA disassembly occurred normally, FA
regeneration at 60min and 2h (not shown) was defective in
SYF-ErbB2 cells, and Herceptin fails to regulate FA assembly and
disassembly using phosphor-FAK-Y397 as a marker for FA.
However, when Src is re-expressed in SYF-ErbB2 cells, FA
disassembly and reassembly occurred at corresponding time
points, and Herceptin gained its function as an FA stabiliser in
Src-reconstituted cells (Figure 6C). These results correlate with the
inhibitory effect of Herceptin on cell invasion (Figure 6D).
Moreover, we observed that cell invasion was significantly
enhanced in ErbB2-positive and Src-reconstituted cells as com-
pared with Src-deficient cells. Although Herceptin activity was
clearly Src and FAK dependent, we noted that Herceptin was still
able to slightly reduce the invasion of the non-reconstituted
SYF-ErbB2 cells (Figure 6D).
DISCUSSION
Mounting experimental and clinical evidence supports that
primary breast cancer dissemination to distant organs is an early
genetic event that can occur during cancer development (Weigelt
et al, 2005). The early cancer cell migration involves a network of
FA and cystoskeletal proteins regulated by growth factor receptors,
integrins, and components of the ECM. Focal adhesions are
specialised structures that mediate the formation and extension of
finger-like protrusions required for cell attachment, cell contrac-
tion, cell migration, and invasion of neighbouring structures. One
of the key proteins involved in this dynamic process is FAK, which
in conjunction with partners of the FAs network couples growth
factor receptors and integrins to FAs and regulates early cell
migration. Focal adhesion kinase is found to play a critical role in
oncogenic transformation and invasion induced by members of
the ErbB family (Sieg et al, 2000; Benlimame et al, 2005) as well as
chemical carcinogens (McLean et al, 2004).
In this study, we document that in ErbB2-positive invasive
breast cancer cells FA disassembly is rapid compared with ErbB2
negative cells where FAs are more stable and prominent at the cell
periphery. This supports an important function of ErbB2 signalling
in the regulation of FA turnover in invasive breast cancer cells.
Herceptin binds to the juxtamembrane region of the ErbB2
ectodomain (Cho et al, 2003), a region involved in receptor
dimerisation and transmembrane signalling. Noticeable, the
antiproliferative activity of Herceptin on ErbB2-positive breast
cancer cells is minimal compared with its drastic anti-invasive
activity. Several debated mechanisms have been reported for the
therapeutic activity of Herceptin. For instance, Herceptin has been
reported to induce downregulation of ErbB2 receptor activity by
promoting its recycling, internalisation, and/or lysosomal degra-
dation (Klapper et al, 2000; Friedman et al, 2005); inhibition of
ErbB signalling, in particular the PI-3K/Akt pathway (Ignatoski
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Figure 5 Herceptin inhibits ErbB2–Src interaction, Src kinase activity,
and FAK kinase activity. (A) Herceptin induces Src dissociation from ErbB2.
MDA231-ErbB2 cells were serum-starved for 24h, stimulated with
10ngml
 1 HRG b1 and then treated with IgG1 ( )o r5 mgml
 1
Herceptin (Hcp) (þ) for 1h. Anti-ErbB2 immunoprecipitates were blotted
with Src antibody to detect ErbB2 bound to Src. The membrane was then
stripped and reprobed with anti-ErbB2 antibody. (B) Herceptin inhibits Src
kinase activity. Cell lysates from cells collected under similar condition as in
(A) were immunoprecipitated with Src antibody. Immunocomplexes were
subjected to Src kinase assays using enolase as a substrate (top panel). The
levels of Src used in the kinase assay were monitored by immunoblotting of
immunoprecipitates with anti-Src antibody (lower panel). (C) Herceptin
decreases FAK activity in a time-dependent manner. MDA231-ErbB2 cells
were serum-starved for 24h, stimulated with 10ngml
 1 HRG b1 and then
kept in suspension or in monolayer treated with IgG1(control) or 5mgml
 1
Herceptin for the indicated times. Cell lysates were used for the FAK assay
as described in Materials and Methods. Each bar represents the average of
three independent experiments±s.d.
Figure 6 Herceptin-induced regulation of FA turnover is FAK and Src dependent. (A) Left panel: immunoblotting of FAK in FAK
 / -ErbB2, and their
respective FAK-reconstituted cells, and FAK
þ/þ-ErbB2 cells. Right panel: SYF cells (Src, Yes, and Fyn triple knockout) and Src-reconstituted SYF cells
(SYF-c-Src) were engineered to express ErbB2. Cell lysates from control and ErbB2-expressing cells were used to confirm ErbB2 and Src expression by
immunoblotting. As an internal control GAPDH was used . (B) Herceptin fails to regulate FA turnover in FAK-deficient cells overexpressing ErbB2 (FAK
 / -
ErbB2). Cells were treated with mouse IgG1 ( )o r5mgml
 1 Herceptin (Hcp) (þ) for 1h followed by 10mM nocodazole (NZ) treatment for 4h (0min).
Cells were then cultured in nocodazole-free medium for the indicated times. Note that FAK
 / -ErbB2 are resistant to microtubule-induced disassembly of
FA after nocodazole washout, and Herceptin had no effect on the turnover (60min) of FA immunostained with vinculin. In contrast, immunofluorescence
labelling of phosphor-FAK-Y397 showed that the restoration of FAK in FAK
 / -ErbB2 cells rescued the effect of Herceptin on FAs assembly (60min). Scale
bar, 30mm. (C) Herceptin failed to regulate FA turnover in SYF-ErbB2 cells. Similar vinculin staining was shown in the absence or presence of Herceptin
(Hcp) at 0 and 60min after nocadazole (NZ) washout. In contrast, Herceptin was able to regulate FA turnover (60min) in Src-reconstituted SYF-ErbB2
(SYF-Src-ErbB2) cells. Scale bar, 30mm. (D) Herceptin treatment was more potent in inhibiting invasion of SYF-Src-ErbB2 compared with SYF-ErbB2. Cell
invasion was determined using the Boyden chamber assay as described in Materials and Methods. Results are expressed as the mean of at least three
experiments and three fields per condition±s.d.
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set al, 2000; Yakes et al, 2002) and activation of PTEN (Nagata et al,
2004), leading to inhibition of cell proliferation and enhanced cell
susceptibility to apoptosis; decreased cleavage of ErbB2 receptor
ectodomain, which prevents the formation of the active truncated
form of the receptor (Molina et al, 2001); antibody-dependent
cell-mediated cytotoxicity by engaging Fcg receptors on immune
effector cells through the IgG1 Fc region of Herceptin (Clynes et al,
2000); increased chemotherapy-induced DNA damage (You et al,
1998; Pietras et al, 1999), and indirect antiangiogenic effect by
inhibition of angiogenic factor secretion, for example, VEGF, by
cancer cells (Yen et al, 2000; Izumi et al, 2002; Klos et al, 2003).
The implications of these mechanisms for Herceptin antimetastatic
activity in vivo remains debated. For instance, a study by Yoeli-
Lerner et al (2005) showed that activation of Akt, but not its
downregulation, inhibits breast cancer invasion through inhibition
of the transcription factor NFAT. This study suggests that
inhibition of Akt signalling by Herceptin cannot explain Herceptin
antimetastatic activity. Indeed, downregulation of Akt by siRNA to
a level that is similar to that obtained following Herceptin
treatment, only modestly reduced the anti-invasive activity when
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scompared with Herceptin treatment or downregulation of FAK by
siRNA. This is in agreement with the study by Yoeli-Lerner et al
(2005).
The inhibition of FA disassembly by Herceptin, resulted in more
stable FA sites at the cell membrane protrusions, in contrast to
IgG-treated cells where FA turnover is rapid. This pattern of
reduced FA disassembly by Herceptin resembled the appearance of
FAs in several cell motility-deficient cells, including FAK
 /  cells
(Ren et al, 2000; Sieg et al, 2000; Webb et al, 2004) and Src
 /  cells
(Ilic et al, 1995; Cary et al, 2002; Yeo et al, 2006). Indeed, we
showed that Herceptin-induced inhibition of FA disassembly and
cell invasion were lost in FAK- and Src-deficient cells over-
expressing ErbB2 but are rescued upon re-expression of FAK or
Src. Cell invasion signalling occurs through distinct pathways, and
in particular FA signalling, which is critical for the formation and
turnover of new adhesions at the leading edge of motile cancer
cells (Rottner et al, 1999; Smilenov et al, 1999). The Src–FAK
complex has been implicated as a key regulator for FA turnover,
namely the rate of adhesion formation, disassembly, and/or
maturation (Schaller et al, 1994; Fincham and Frame, 1998; Sieg
et al, 2000; Volberg et al, 2001). In particular, Yeo et al (2006) and
Webb et al (2004) have reported a key function for the Src–FAK
complex in FA disassembly. Activation of the Src–FAK signalling
is generally reported to promote F-actin stress fiber assembly and
suppresses RhoA activity (Ren et al, 2000); these events can
contribute to FA disassembly and enhanced cell migration (Ridley
and Hall, 1992; Rottner et al, 1999). Our study excludes the
possibility that Herceptin-induced changes in FA turnover are
mediated by modulation of the Rho GTPase pathway, as no
differences were noted in activated RhoA in control vs Herceptin-
treated cells, in agreement with a study by Webb et al (2004) where
FA turnover was shown to be independent from RhoA activity.
The FAK–Src signalling has been shown to interrupt the
maturation of FAs by promoting their disassembly (Webb et al,
2004). This in turn allows continuous adhesion turnover as the
cells protrude and migrate. When the Src–FAK signalling is
inhibited, adhesion disassembly in protrusive regions is impaired
in the presence of Herceptin, similar to Src- and FAK-deficient
cells. Our study showes that the exposure of ErbB2-positive cells to
Herceptin inhibits Src binding to ErbB2 and Src kinase activity.
Under similar condition, FAK activity is inhibited by Herceptin.
This novel FAK inhibitory mechanism for Herceptin further
establishes a connection between ErbB, Src, and FAK signalling.
Therefore, we reasoned that Herceptin, by inhibiting Src and FAK
activities, lead to inhibition of FA turnover, which manifest by
increased FA stability and reduced cell invasion (a schematic
model where Herceptin-mediated regulation of FAs is contrasted
with earlier reported mechanisms for Herceptin as shown in
Supplementary Figure 2).
However, there is a multitude of additional Src- and FAK-
regulated pathways that may account for the regulation of FA
turnover by ErbB signalling, which cannot be ruled out at present.
For instance, although Src SH2 interaction with FAK is necessary
for appropriate recruitment of Src and FAK to FA in migratory
cells, the FAK–Src complex can also regulate the phosphorylation
of the adaptor proteins paxillin and p130Cas (Bellis et al, 1995;
Cary et al, 1998); the latter can bind independently to both FAK
and Src. Phosphorylation of both paxillin and p130Cas creates
binding sites for the SH2 domain of the Crk adaptor protein
(Iwahara et al, 2004), which can impact on the maturation of FA
complexes to stable FAs or turn them rapidly (Webb et al, 2004;
Zaidel-Bar et al, 2007). Indeed, cells deficient in p130Cas or
paxillin, similar to FAK- and Src-deficient cells, have impaired
adhesion disassembly and reduced motility (Webb et al, 2004). In
contrast to FAK-deficient cells, we noted that SYF-ErbB2 cells
acquired a slight and reproducible increase in invasiveness,
although to a much lower extent than the Src-reconstituted SYF-
ErbB2 cells, and Herceptin reduced invasion of these Src-deficient
cells (Figure 6D). This would suggest that ErbB signalling and
Herceptin may also regulate cell invasiveness through an Src-
independent mechanism(s). These alternative mechanisms for the
regulation of FA turnover highlight the clinical potential of
inhibitors of FA turnover for the management of invasive cancers.
Several investigational drugs, including small molecule kinase
inhibitors against FA and its homologue Pyk2 (Roberts et al, 2008),
are at the stage of early clinical trials and may prove more efficient
modulators of FA turnover and hence can prevent the progression
of invasive cancers to metastases. This is particularly important as
many of the FA proteins, such as ErbB receptors, are over-
expressed in invasive cancers (Behmoaram et al, 2008).
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